Business
Evogene Provides 2020 Year-End Update for CRISPR-IL Consortium
Progress includes completion of a first version of the artificial intelligence-driven platform for genome-editing REHOVOT, Israel, Jan. 5, 2021 /PRNewswire/
About this update from Evogene Ltd.
[{"type":"text","content":"Progress includes completion of a first version of the artificial intelligence-driven platform for genome-editing\n\n\nREHOVOT, Israel, Jan. 5, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product development across several market segments, provided today a year-end update for the CRISPR-IL consortium, of which it is a member and Evogene's CSO, Dr. Eyal Emmanuel, serves as the consortium's Chairman. The CRISPR-IL consortium, which is supported by the Israeli Innovation Authority, was established to develop an artificial intelligence-based system, for CRISPR-CAS based workflows, \"Go-Genome\", providing end-to-end genome-editing, with improved precision and efficiency.\n \n \nThe Company announces today, CRISPR-IL's completion of a first version of the artificial intelligence-driven platform for genome-editing, CRISPR-CAS based, design; a major milestone in the development roadmap of \"Go-Genome\". Also announced is the addition of two new members, Better Seeds and FreeZem, active in the areas of agriculture and alternative protein sourced from insects, respectively. The addition of these two companies is expected to widen the system's applicability. \nCRISPR-CAS is a revolutionizing genome-editing technology that enables precise genomic changes, which are expected to lead to the development of a new set of products and services. The products and services are expected to include human therapeutics such as CAR-T treatments and curing monogenic diseases, and agricultural uses such as adding nutritional value to food products, among others. This technology can result in products and services in a wide range of markets that could potentially reach a total market size of $500 billion in 2025.[1] \nWhile current CRISPR-CAS based workflows target precise areas within the DNA, these workflows still face several challenges, which prevent more extensive use of this technology, including (i) accidental off-target modification, (ii) inefficient modifications requiring repeated trials, and (iii) inaccurate measuring tools to ascertain that the modification was effective as intended. The CRISPR-IL consortium was established to address these challenges. \nEvogene led the consortium's work package for the development of this first version of a geno...